Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Compass Pathways's share price for the quarter that ended in Jun. 2024 was €5.6. Compass Pathways's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 68.39 Mil. Therefore, Compass Pathways's market cap for the quarter that ended in Jun. 2024 was €382.97 Mil.
Compass Pathways's quarterly market cap
increased
from Dec. 2023 (€507.94 Mil) to Mar. 2024 (€533.07 Mil) but then
declined
from Mar. 2024 (€533.07 Mil) to Jun. 2024 (€382.97 Mil).
Compass Pathways's annual market cap
declined
from Dec. 2021 (€806.78 Mil) to Dec. 2022 (€324.00 Mil) but then
increased
from Dec. 2022 (€324.00 Mil) to Dec. 2023 (€507.94 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Compass Pathways's Enterprise Value for Today is €248.98 Mil.
Compass Pathways Market Cap Historical Data
The historical data trend for Compass Pathways's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Pathways's Market Cap
For the Medical Care Facilities subindustry, Compass Pathways's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways's Market Cap Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Market Cap distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Market Cap falls into.
Compass Pathways Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Compass Pathways's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (STU:5Y6) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Compass Pathways Market Cap Related Terms
Thank you for viewing the detailed overview of Compass Pathways's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:5Y6 has been successfully added to your 